Your browser doesn't support javascript.
loading
International trends in antipsychotic use: A study in 16 countries, 2005-2014.
Hálfdánarson, Óskar; Zoëga, Helga; Aagaard, Lise; Bernardo, Miquel; Brandt, Lena; Fusté, Anna Coma; Furu, Kari; Garuoliené, Kristina; Hoffmann, Falk; Huybrechts, Krista F; Kalverdijk, Luuk J; Kawakami, Koji; Kieler, Helle; Kinoshita, Takuya; Litchfield, Melisa; López, Soffy C; Machado-Alba, Jorge E; Machado-Duque, Manuel E; Mahesri, Mufaddal; Nishtala, Prasad S; Pearson, Sallie-Anne; Reutfors, Johan; Saastamoinen, Leena K; Sato, Izumi; Schuiling-Veninga, Catharina C M; Shyu, Yu-Chiau; Skurtveit, Svetlana; Verdoux, Hélène; Wang, Liang-Jen; Yahni, Corinne Zara; Bachmann, Christian J.
Afiliación
  • Hálfdánarson Ó; Centre of Public Health Sciences, Faculty of Medicine, University of Iceland, Reykjavik, Iceland.
  • Zoëga H; Centre of Public Health Sciences, Faculty of Medicine, University of Iceland, Reykjavik, Iceland; Medicines Policy Research Unit, Centre for Big Data Research in Health, University of New South Wales, Sydney, Australia.
  • Aagaard L; Life Science Team, Bech-Bruun Law Firm, Copenhagen, Denmark.
  • Bernardo M; Barcelona Clinic Schizophrenia Unit, Neuroscience Institute, and Hospital Clínic, Department of Medicine, Barcelona University, and Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), and Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Barcelona, Spain.
  • Brandt L; Centre for Pharmacoepidemiology, Department of Medicine, Solna, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
  • Fusté AC; Pharmacy Department of Barcelona Health Region, Catalan Health Service (CatSalut), Barcelona, Spain.
  • Furu K; Division of Mental and Physical Health, Norwegian Institute of Public Health, Norway.
  • Garuoliené K; Medicines Reimbursement Department, National Health Insurance Fund of the Republic of Lithuania, Vilnius, Lithuania, and Faculty of Medicine, Department of Pathology, Forensic Medicine and Pharmacology, Vilnius University, Lithuania.
  • Hoffmann F; Department of Health Services Research, Carl von Ossietzky University Oldenburg, Germany.
  • Huybrechts KF; Brigham and Women׳s Hospital, Harvard Medical School, Boston, MA, USA.
  • Kalverdijk LJ; University of Groningen, University Medical Center Groningen, Department of Psychiatry, The Netherlands.
  • Kawakami K; Department of Pharmacoepidemiology and Clinical Research Management, Graduate School of Medicine and Public Health, Kyoto University, Japan.
  • Kieler H; Centre for Pharmacoepidemiology, Department of Medicine, Solna, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
  • Kinoshita T; Department of Pharmacoepidemiology and Clinical Research Management, Graduate School of Medicine and Public Health, Kyoto University, Japan.
  • Litchfield M; Medicines Policy Research Unit, Centre for Big Data Research in Health, University of New South Wales, Sydney, Australia.
  • López SC; Grupo de Investigación en Farmacoepidemiología y Farmacovigilancia, Universidad Tecnológica de Pereira - Audifarma S.A., Pereira, Colombia.
  • Machado-Alba JE; Grupo de Investigación en Farmacoepidemiología y Farmacovigilancia, Universidad Tecnológica de Pereira - Audifarma S.A., Pereira, Colombia.
  • Machado-Duque ME; Grupo de Investigación en Farmacoepidemiología y Farmacovigilancia, Universidad Tecnológica de Pereira - Audifarma S.A., Pereira, Colombia.
  • Mahesri M; Brigham and Women׳s Hospital, Harvard Medical School, Boston, MA, USA.
  • Nishtala PS; New Zealand׳s National School of Pharmacy, University of Otago, Dunedin, New Zealand.
  • Pearson SA; Medicines Policy Research Unit, Centre for Big Data Research in Health, University of New South Wales, Sydney, Australia.
  • Reutfors J; Centre for Pharmacoepidemiology, Department of Medicine, Solna, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
  • Saastamoinen LK; Kela Research, The Social Insurance Institution, Helsinki, Finland.
  • Sato I; Department of Pharmacoepidemiology and Clinical Research Management, Graduate School of Medicine and Public Health, Kyoto University, Japan.
  • Schuiling-Veninga CCM; Unit of Pharmacotherapy, -Epidemiology and -Economics, Department of Pharmacy, University of Groningen, The Netherlands.
  • Shyu YC; Community Medicine Research Center, Chang Gung Memorial Hospital, Keelung, Taiwan, and Institute of Molecular Biology, Academia Sinica, Taipei, and Department of Nutrition, Chang Gung University of Science and Technology, Kwei-Shan, Taiwan.
  • Skurtveit S; Division of Mental and Physical Health, Norwegian Institute of Public Health, Norway.
  • Verdoux H; University of Bordeaux, INSERM, Bordeaux Population Health Research Center, Team Pharmaco-epidemiology, UMR 1219, F33000 Bordeaux, France.
  • Wang LJ; Department of Child & Adolescent Psychiatry, Kaohsiung Chang Gung Memorial Hospital, and Chang Gung University College of Medicine, Kaohsiung, Taiwan.
  • Yahni CZ; Pharmacy Department of Barcelona Health Region, Catalan Health Service (CatSalut), Barcelona, Spain.
  • Bachmann CJ; Freelance Researcher, Marburg, Germany. Electronic address: chrstn.bchmnn@gmail.com.
Eur Neuropsychopharmacol ; 27(10): 1064-1076, 2017 10.
Article en En | MEDLINE | ID: mdl-28755801
ABSTRACT
The objective of this study was to assess international trends in antipsychotic use, using a standardised methodology. A repeated cross-sectional design was applied to data extracts from the years 2005 to 2014 from 16 countries worldwide. During the study period, the overall prevalence of antipsychotic use increased in 10 of the 16 studied countries. In 2014, the overall prevalence of antipsychotic use was highest in Taiwan (78.2/1000 persons), and lowest in Colombia (3.2/1000). In children and adolescents (0-19 years), antipsychotic use ranged from 0.5/1000 (Lithuania) to 30.8/1000 (Taiwan). In adults (20-64 years), the range was 2.8/1000 (Colombia) to 78.9/1000 (publicly insured US population), and in older adults (65+ years), antipsychotic use ranged from 19.0/1000 (Colombia) to 149.0/1000 (Taiwan). Atypical antipsychotic use increased in all populations (range of atypical/typical ratio 0.7 (Taiwan) to 6.1 (New Zealand, Australia)). Quetiapine, risperidone, and olanzapine were most frequently prescribed. Prevalence and patterns of antipsychotic use varied markedly between countries. In the majority of populations, antipsychotic utilisation and especially the use of atypical antipsychotics increased over time. The high rates of antipsychotic prescriptions in older adults and in youths in some countries merit further investigation and systematic pharmacoepidemiologic monitoring.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Antipsicóticos / Quimioterapia Tipo de estudio: Observational_studies / Prevalence_studies / Risk_factors_studies Límite: Adolescent / Adult / Aged / Child / Child, preschool / Humans / Infant / Middle aged / Newborn Idioma: En Revista: Eur Neuropsychopharmacol Asunto de la revista: PSICOFARMACOLOGIA Año: 2017 Tipo del documento: Article País de afiliación: Islandia

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Antipsicóticos / Quimioterapia Tipo de estudio: Observational_studies / Prevalence_studies / Risk_factors_studies Límite: Adolescent / Adult / Aged / Child / Child, preschool / Humans / Infant / Middle aged / Newborn Idioma: En Revista: Eur Neuropsychopharmacol Asunto de la revista: PSICOFARMACOLOGIA Año: 2017 Tipo del documento: Article País de afiliación: Islandia